Global Lung Cancer Therapeutics Market Research and Forecast, 2018-2023

Orion Market Research Pvt. Ltd.

Industry Market Research Report and Consulting

Lung cancer therapeutics market, size, share, market intelligence, company profiles, market trends, strategy, research report, analysis, forecast 2018-2023

Rise in incidence & prevalence rate of lung cancer & successful clinical trials of lung cancer drugs are driving the market”

— OMR Analyst

INDORE, INDIA, March 9, 2018 / — Orion Market Research (OMR), recently published a market research report on global lung cancer therapeutics market. According to OMR analysis, the global lung cancer therapeutics market is expected to grow with CAGR of 13% during 2018-2023. The global lung cancer therapeutics market is segmented on the basis of drugs, therapy, end-user and geography. The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, patent analysis, pipeline analysis, market determinants, key company analysis, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

The full report of global lung cancer therapeutics market is available at

“The global lung cancer therapeutics market is driven by various pivotal factors which include rising incidence and prevalence rate of cancer, successful clinical trials and FDA clearances to critical lung cancer drugs and surgeries. Other key factors such as government investments, grants and private investment are also boosting the market growth. Significant R&D in lung cancer drugs and a shift towards uses of personalized medicines are creating considerable scope for the market. There is significant growth in the lung cancer drugs market due to the higher number of prescriptions and consumption of lung cancer drugs across the globe.

Global lung cancer by region is segmented on the basis of regions which includes North America, Europe, APAC and RoW. Global lung cancer therapeutics market is expected to perform significantly in North America followed by Europe due to a high prevalence rate of lung cancer market. APAC region is predicted to contribute at a modest rate due to the considerable adoption of personalized drugs and improved healthcare spending.

Companies Profiled
1. Abbvie
2. Agennix
3. Amgen
4. AstraZeneca
5. Boehringer Ingelheim
6. Celgene
7. Celldex
8. Eisai
9. Eli Lilly
10. F. Hoffmann-La Roche
11. GlaxoSmithKline
12. Helsinn
13. Imclone
14. Merck Serono
15. Novartis
16. Oncogenex
17. OSI Pharmaceuticals
18. Peregrine
19. Pfizer, Inc.
20. Pierre Fabre
21. Qiagen
22. Sanofi
23. Synta
24. Telik
25. Teva Pharmaceutical

For Related Reports visit:

The report covers:
• Comprehensive research methodology of lung cancer therapeutics market
• In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global lung cancer therapeutics market
• Insights about market determinants which are stimulating the global lung cancer therapeutics market
• Detailed and extensive market segments with regional distribution of forecasted revenues
• Extensive profiles and recent developments of market players

About Orion Market Research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
email us here

Source: EIN Presswire